Retatrutide Results Timeline
What the standard Retatrutide research protocol looks like phase by phase, over a typical 12–48 weeks cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Quick Facts
FREQUENCYOnce weekly
CYCLE LENGTH12–48 weeks
DOSE RANGE2–12 mg/week (gradual escalation)
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Weeks 1–4
Target dose: 2 mg (2000 mcg)
Escalation
Weeks 5–8
Target dose: 4 mg (4000 mcg)
Escalation
Weeks 9–12
Target dose: 6 mg (6000 mcg)
Maintenance
Weeks 13+
Target dose: 8 mg (8000 mcg)
Reported in Research
- ✓Phase 2 trials demonstrated up to 24% body weight loss at 48 weeks.
- ✓Start at 2 mg weekly for 4 weeks.
- ✓Increase by 2–4 mg every 4 weeks as tolerated.
- ✓Minimum 24 weeks; clinical trials extended to 48 weeks.
This timeline reflects the structure of the standard Retatrutide research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.